Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Microenvironment
Published in: Cancer Microenvironment 1/2008

Open Access 01-12-2008 | Review Paper

Emerging Roles of PAR-1 and PAFR in Melanoma Metastasis

Authors: Vladislava O. Melnikova, Gabriel J. Villares, Menashe Bar-Eli

Published in: Cancer Microenvironment | Issue 1/2008

Login to get access

Abstract

Melanoma growth, angiogenesis and metastatic progression are strongly promoted by the inflammatory tumor microenvironment due to high levels of cytokine and chemokine secretion by the recruited inflammatory and stromal cells. In addition, platelets and molecular components of procoagulant pathways have been recently emerging as critical players of tumor growth and metastasis. In particular, thrombin, through the activity of its receptor protease-activated receptor-1 (PAR-1), regulates tumor cell adhesion to platelets and endothelial cells, stimulates tumor angiogenesis, and promotes tumor growth and metastasis. Notably, in many tumor types including melanoma, PAR-1 expression directly correlates with their metastatic phenotype and is directly responsible for the expression of interleukin-8, matrix metalloproteinase-2 (MMP-2), vascular endothelial growth factor, platelet-derived growth factor, and integrins. Another proinflammatory receptor–ligand pair, platelet-activating factor (PAF) and its receptor (PAFR), have been shown to act as important modulators of tumor cell adhesion to endothelial cells, angiogenesis, tumor growth and metastasis. PAF is a bioactive lipid produced by a variety of cells from membrane glycerophospholipids in the same reaction that releases arachidonic acid, and can be secreted by platelets, inflammatory cells, keratinocytes and endothelial cells. We have demonstrated that in metastatic melanoma cells, PAF stimulates the phosphorylation of cyclic adenosine monophosphate response element-binding protein (CREB) and activating transcription factor 1 (ATF-1), which results in overexpression of MMP-2 and membrane type 1-MMP (membrane type 1-MMP). Since only metastatic melanoma cells overexpress CREB/ATF-1, we propose that metastatic melanoma cells are better equipped than their non-metastatic counterparts to respond to PAF within the tumor microenvironment. The evidence supporting the hypothesis that the two G-protein coupled receptors, PAR-1 and PAFR, contribute to the acquisition of the metastatic phenotype of melanoma is presented and discussed.
Literature
1.
Fidler IJ (2003) The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nat Rev Cancer 3(6):453–458PubMed
2.
Balkwill F, Mantovani A (2001) Inflammation and cancer: back to Virchow. Lancet 357(9255):539–545PubMed
3.
Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420(6917):860–867PubMed
4.
Mantovani A (2005) Cancer: inflammation by remote control. Nature 435(7043):752–753PubMed
5.
Pikarsky E et al (2004) NF-kappa B functions as a tumour promoter in inflammation-associated cancer. Nature 431(7007):461–466PubMed
6.
Smalley KS, Lioni M, Herlyn M (2005) Targeting the stromal fibroblasts: a novel approach to melanoma therapy. Expert Rev Anticancer Ther 5(6):1069–1078PubMed
7.
8.
Tlsty TD, Coussens LM (2006) Tumor stroma and regulation of cancer development. Annu Rev Pathol 1:119–150PubMed
9.
Haass NK, Herlyn M (2005) Normal human melanocyte homeostasis as a paradigm for understanding melanoma. J Investig Dermatol Symp Proc 10(2):153–163PubMed
10.
Lee JT, Herlyn M (2006) Microenvironmental influences in melanoma progression. J Cell Biochem 101(4):862–872
11.
Postovit LM et al (2006) Influence of the microenvironment on melanoma cell fate determination and phenotype. Cancer Res 66(16):7833–7836PubMed
12.
Schwarz T, Luger TA (1989) Effect of UV irradiation on epidermal cell cytokine production. J Photochem Photobiol B 4(1):1–13PubMed
13.
Marathe GK et al (2005) Ultraviolet B radiation generates platelet-activating factor-like phospholipids underlying cutaneous damage. J Biol Chem 280(42):35448–35457PubMed
14.
Pei Y et al (1998) Activation of the epidermal platelet-activating factor receptor results in cytokine and cyclooxygenase-2 biosynthesis. J Immunol 161(4):1954–1961PubMed
15.
Walterscheid JP, llrich SE, Nghiem DX (2002) Platelet-activating factor, a molecular sensor for cellular damage, activates systemic immune suppression. J Exp Med 195(2):171–179PubMed
16.
Ullrich SE (2005) Mechanisms underlying UV-induced immune suppression. Mutat Res 571(1–2):185–205PubMed
17.
Hsu MY, Meier F, Herlyn M (2002) Melanoma development and progression: a conspiracy between tumor and host. Differentiation 70(9–10):522–536PubMed
18.
Gaggioli C et al (2007) Fibroblast-led collective invasion of carcinoma cells with differing roles for RhoGTPases in leading and following cells. Nat Cell Biol 9(12):1392–1400PubMed
19.
De Palma M et al (2005) Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 8(3):211–226PubMed
20.
Lewis CE, De Palma M, Naldini L (2007) Tie2-expressing monocytes and tumor angiogenesis: regulation by hypoxia and angiopoietin-2. Cancer Res 67(18):8429–8432PubMed
21.
Coussens LM et al (2000) MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 103(3):481–490PubMed
22.
Gasic GJ, Gasic TB, Stewart CC (1968) Antimetastatic effects associated with platelet reduction. Proc Natl Acad Sci U S A 61(1):46–52PubMed
23.
Nierodzik ML, Karpatkin S (2006) Thrombin induces tumor growth, metastasis, and angiogenesis: evidence for a thrombin-regulated dormant tumor phenotype. Cancer Cell 10(5):355–362PubMed
24.
Nierodzik ML et al (1998) Protease-activated receptor 1 (PAR-1) is required and rate-limiting for thrombin-enhanced experimental pulmonary metastasis. Blood 92(10):3694–3700PubMed
25.
Gupta RA, Dubois RN (2001) Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer 1(1):11–21PubMed
26.
Affara NI, Coussens LM (2007) IKK alpha at the crossroads of inflammation and metastasis. Cell 129(1):25–26PubMed
27.
Brown JR, DuBois RN (2004) Cyclooxygenase as a target in lung cancer. Clin Cancer Res 10(12 Pt 2):4266s–4269sPubMed
28.
Dauer DJ et al (2005) Stat3 regulates genes common to both wound healing and cancer. Oncogene 24(21):3397–3408PubMed
29.
Robinson SC, Coussens LM (2005) Soluble mediators of inflammation during tumor development. Adv Cancer Res 93:159–187PubMed
30.
Nyormoi O, Bar-Eli M (2003) Transcriptional regulation of metastasis-related genes in human melanoma. Clin Exp Metastasis 20(3):251–263PubMed
31.
Bromberg ME et al (1995) Tissue factor promotes melanoma metastasis by a pathway independent of blood coagulation. Proc Natl Acad Sci U S A 92(18):8205–8209PubMed
32.
Fischer EG, Ruf W, Mueller BM (1995) Tissue factor-initiated thrombin generation activates the signaling thrombin receptor on malignant melanoma cells. Cancer Res 55(8):1629–1632PubMed
33.
Ruf W, Mueller BM (2006) Thrombin generation and the pathogenesis of cancer. Semin Thromb Hemost 32(Suppl 1):61–68PubMed
34.
Tellez C, Bar-Eli M (2003) Role and regulation of the thrombin receptor (PAR-1) in human melanoma. Oncogene 22(20):3130–3137PubMed
35.
Kepner N, Lipton A (1981) A mitogenic factor for transformed fibroblasts from human platelets. Cancer Res 41(2):430–432PubMed
36.
Mohle R et al (1997) Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc Natl Acad Sci U S A 94(2):663–668PubMed
37.
Li JJ et al (2001) Thrombin induces the release of angiopoietin-1 from platelets. Thromb Haemost 85(2):204–206PubMed
38.
Boucharaba A et al (2004) Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer. J Clin Invest 114(12):1714–1725PubMed
39.
Nieswandt B et al (1999) Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Res 59(6):1295–1300PubMed
40.
Haralabopoulos GC et al (1997) Thrombin promotes endothelial cell alignment in Matrigel in vitro and angiogenesis in vivo. Am J Physiol 273(1 Pt 1):C239–C245PubMed
41.
Ruf W (2007) Tissue factor and PAR signaling in tumor progression. Thromb Res 120(Suppl 2):S7–S12PubMed
42.
Hansen KK, Saifeddine M, Hollenberg MD (2004) Tethered ligand-derived peptides of proteinase-activated receptor 3 (PAR3) activate PAR1 and PAR2 in Jurkat T cells. Immunology 112(2):183–190PubMed
43.
O’Brien PJ et al (2001) Protease activated receptors: theme and variations. Oncogene 20(13):1570–1581PubMed
44.
Boire A et al (2005) PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell 120(3):303–313PubMed
45.
Even-Ram SC et al (2001) Tumor cell invasion is promoted by activation of protease activated receptor-1 in cooperation with the alpha v beta 5 integrin. J Biol Chem 276(14):10952–10962PubMed
46.
Wojtukiewicz MZ et al (1992) Thrombin enhances tumor cell adhesive and metastatic properties via increased alpha IIb beta 3 expression on the cell surface. Thromb Res 68(3):233–245PubMed
47.
Senger DR et al (1996) Stimulation of endothelial cell migration by vascular permeability factor/vascular endothelial growth factor through cooperative mechanisms involving the alphavbeta3 integrin, osteopontin, and thrombin. Am J Pathol 149(1):293–305PubMed
48.
Nierodzik ML et al (1996) Presence of the seven transmembrane thrombin receptor on human tumour cells: effect of activation on tumour adhesion to platelets and tumor tyrosine phosphorylation. Br J Haematol 92(2):452–457PubMed
49.
Zucker S et al (1995) Thrombin induces the activation of progelatinase A in vascular endothelial cells. Physiologic regulation of angiogenesis. J Biol Chem 270(40):23730–23738PubMed
50.
Shimizu S et al (2000) Thrombin stimulates the expression of PDGF in lung epithelial cells. Am J Physiol Lung Cell Mol Physiol 279(3):L503–L510PubMed
51.
Ueno A et al (1996) Thrombin stimulates production of interleukin-8 in human umbilical vein endothelial cells. Immunology 88(1):76–81PubMed
52.
Cucina A et al (1999) Thrombin induces production of growth factors from aortic smooth muscle cells. J Surg Res 82(1):61–66PubMed
53.
Huang YQ et al (2001) Thrombin induces increased expression and secretion of VEGF from human FS4 fibroblasts, DU145 prostate cells and CHRF megakaryocytes. Thromb Haemost 86(4):1094–1098PubMed
54.
Massi D et al (2005) Expression of protease-activated receptors 1 and 2 in melanocytic nevi and malignant melanoma. Hum Pathol 36(6):676–685PubMed
55.
Tellez CS et al (2007) Quantitative analysis of melanocytic tissue array reveals inverse correlation between activator protein-2alpha and protease-activated receptor-1 expression during melanoma progression. J Invest Dermatol 127(2):387–393PubMed
56.
Even-Ram S et al (1998) Thrombin receptor overexpression in malignant and physiological invasion processes. Nat Med 4(8):909–914PubMed
57.
Kaushal V et al (2006) Thrombin receptor expression is upregulated in prostate cancer. Prostate 66(3):273–282PubMed
58.
Rudroff C et al (1998) Characterization of functional thrombin receptors in human pancreatic tumor cells (MIA PACA-2). Pancreas 16(2):189–194PubMed
59.
Wojtukiewicz MZ et al (1995) Solid tumor cells express functional “tethered ligand” thrombin receptor. Cancer Res 55(3):698–704PubMed
60.
Tellez C et al (2003) Loss of activator protein-2alpha results in overexpression of protease-activated receptor-1 and correlates with the malignant phenotype of human melanoma. J Biol Chem 278(47):46632–46642PubMed
61.
Benveniste J et al (1979) Semi-synthesis and proposed structure of platelet-activating factor (P.A.F.): PAF-acether an alkyl ether analog of lysophosphatidylcholine. C R Seances Acad Sci D 289(14):1037–1040PubMed
62.
Blank ML et al (1979) Antihypertensive activity of an alkyl ether analog of phosphatidylcholine. Biochem Biophys Res Commun 90(4):1194–1200PubMed
63.
Demopoulos CA, Pinckard RN, Hanahan DJ (1979) Platelet-activating factor. Evidence for 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine as the active component (a new class of lipid chemical mediators). J Biol Chem 254(19):9355–9358PubMed
64.
Benveniste J, Henson PM, Cochrane CG (1972) Leukocyte-dependent histamine release from rabbit platelets. The role of IgE, basophils, and a platelet-activating factor. J Exp Med 136(6):1356–1377PubMed
65.
Marathe GK et al (1999) Inflammatory platelet-activating factor-like phospholipids in oxidized low density lipoproteins are fragmented alkyl phosphatidylcholines. J Biol Chem 274(40):28395–28404PubMed
66.
Uemura Y, Lee TC, Snyder F (1991) A coenzyme A-independent transacylase is linked to the formation of platelet-activating factor (PAF) by generating the lyso-PAF intermediate in the remodeling pathway. J Biol Chem 266(13):8268–8272PubMed
67.
Montrucchio G, Alloatti G, Camussi G (2000) Role of platelet-activating factor in cardiovascular pathophysiology. Physiol Rev 80(4):1669–1699PubMed
68.
Blank ML et al (1988) Stimulation of the de novo pathway for the biosynthesis of platelet-activating factor (PAF) via cytidylyltransferase activation in cells with minimal endogenous PAF production. J Biol Chem 263(12):5656–5661PubMed
69.
Shindou H et al (2007) A single enzyme catalyzes both platelet-activating factor production and membrane biogenesis of inflammatory cells. Cloning and characterization of acetyl-CoA:LYSO-PAF acetyltransferase. J Biol Chem 282(9):6532–6539PubMed
70.
Bito H et al (1994) Cloning, expression and tissue distribution of rat platelet-activating-factor-receptor cDNA. Eur J Biochem 221(1):211–218PubMed
71.
Nakamura M et al (1991) Molecular cloning and expression of platelet-activating factor receptor from human leukocytes. J Biol Chem 266(30):20400–20405PubMed
72.
Ye RD et al (1991) Characterization of a human cDNA that encodes a functional receptor for platelet activating factor. Biochem Biophys Res Commun 180(1):105–111PubMed
73.
Brizzi MF et al (1999) Thrombopoietin stimulates endothelial cell motility and neoangiogenesis by a platelet-activating factor-dependent mechanism. Circ Res 84(7):785–796PubMed
74.
Camussi G et al (1995) Platelet-activating factor directly stimulates in vitro migration of endothelial cells and promotes in vivo angiogenesis by a heparin-dependent mechanism. J Immunol 154(12):6492–6501PubMed
75.
Camussi G et al (1997) Angiogenesis induced in vivo by hepatocyte growth factor is mediated by platelet-activating factor synthesis from macrophages. J Immunol 158(3):1302–1309PubMed
76.
Montrucchio G et al (1994) Tumor necrosis factor alpha-induced angiogenesis depends on in situ platelet-activating factor biosynthesis. J Exp Med 180(1):377–382PubMed
77.
Montrucchio G et al (1997) Nitric oxide mediates angiogenesis induced in vivo by platelet-activating factor and tumor necrosis factor-alpha. Am J Pathol 151(2):557–563PubMed
78.
Montrucchio G et al (1998) Potential angiogenic role of platelet-activating factor in human breast cancer. Am J Pathol 153(5):1589–1596PubMed
79.
Robert EG, Hunt JD (2001) Lipid messengers as targets for antiangiogenic therapy. Curr Pharm Des 7(16):1615–1626PubMed
80.
Bussolino F et al (1995) Platelet activating factor produced in vitro by Kaposi’s sarcoma cells induces and sustains in vivo angiogenesis. J Clin Invest 96(2):940–952PubMedCrossRef
81.
Bussolati B et al (2000) PAF produced by human breast cancer cells promotes migration and proliferation of tumor cells and neo-angiogenesis. Am J Pathol 157(5):1713–1725PubMed
82.
Axelrad TW et al (2004) Platelet-activating factor (PAF) induces activation of matrix metalloproteinase 2 activity and vascular endothelial cell invasion and migration. Faseb J 18(3):568–570PubMed
83.
Deo DD et al (2002) Phosphorylation of STAT-3 in response to basic fibroblast growth factor occurs through a mechanism involving platelet-activating factor, JAK-2, and Src in human umbilical vein endothelial cells. Evidence for a dual kinase mechanism. J Biol Chem 277(24):21237–21245PubMed
84.
Sirois MG, Edelman ER (1997) VEGF effect on vascular permeability is mediated by synthesis of platelet-activating factor. Am J Physiol 272(6 Pt 2):H2746–H2756PubMed
85.
Rollin S et al (2004) VEGF-mediated endothelial P-selectin translocation: role of VEGF receptors and endogenous PAF synthesis. Blood 103(10):3789–3797PubMed
86.
Maliba R et al (2006) Angiopoietins-1 and -2 are both capable of mediating endothelial PAF synthesis: intracellular signalling pathways. Cell Signal 18(11):1947–1957PubMed
87.
Im SY et al (1996) Augmentation of tumor metastasis by platelet-activating factor. Cancer Res 56(11):2662–2665PubMed
88.
Sato S et al (1999) Accelerated proliferation of epidermal keratinocytes by the transgenic expression of the platelet-activating factor receptor. Arch Dermatol Res 291(11):614–621PubMed
89.
Ishii S et al (1997) Bronchial hyperreactivity, increased endotoxin lethality and melanocytic tumorigenesis in transgenic mice overexpressing platelet-activating factor receptor. Embo J 16(1):133–142PubMed
90.
Barber LA, Spandau DF, Rathman SC, Murphy RC, Johnson CA, Kelley SW, Hurwitz SA, Travers JB (1998) Expression of the platelet-activating factor receptor results in enhanced ultraviolet B radiation-induced apoptosis in a human epidermal cell line. J Biol Chem 273(30):18891–18897PubMed
91.
Sheng Y, Birkle DL (1995) Release of platelet activating factor (PAF) and eicosanoids in UVC-irradiated corneal stromal cells. Curr Eye Res 14(5):341–347PubMed
92.
Calignano A et al (1988) Isolation and identification of platelet-activating factor in UV-irradiated guinea pig skin. J Pharmacol Methods 19(1):89–91PubMed
93.
Travers JB et al (1995) Identification of functional platelet-activating factor receptors on human keratinocytes. J Invest Dermatol 105(6):816–823PubMed
94.
De Fabo EC et al (2004) Ultraviolet B but not ultraviolet A radiation initiates melanoma. Cancer Res 64(18):6372–6376PubMed
95.
Noonan FP et al (2001) Neonatal sunburn and melanoma in mice. Nature 413(6853):271–272PubMed
96.
Zhang Q et al (2005) Staphylococcal lipoteichoic acid inhibits delayed-type hypersensitivity reactions via the platelet-activating factor receptor. J Clin Invest 115(10):2855–2861PubMed
97.
Biancone L et al (2003) Platelet-activating factor inactivation by local expression of platelet-activating factor acetyl-hydrolase modifies tumor vascularization and growth. Clin Cancer Res 9(11):4214–4220PubMed
98.
Fallani A et al (2006) Platelet-activating factor (PAF) is the effector of IFN gamma-stimulated invasiveness and motility in a B16 melanoma line. Prostaglandins Other Lipid Mediat 81(3–4):171–177PubMed
99.
Ko HM et al (2007) Critical role for matrix metalloproteinase-9 in platelet-activating factor-induced experimental tumor metastasis. Int J Cancer 120(6):1277–1283PubMed
100.
Mannori G et al (2000) Interaction of tumor cells with vascular endothelia: role of platelet-activating factor. Clin Exp Metastasis 18(1):89–96PubMed
101.
Melnikova VO et al (2006) Platelet-activating factor mediates MMP-2 expression and activation via phosphorylation of cAMP-response element-binding protein and contributes to melanoma metastasis. J Biol Chem 281(5):2911–2922PubMed
102.
Deo DD, Bazan NG, Hunt JD (2004) Activation of platelet-activating factor receptor-coupled G alpha q leads to stimulation of Src and focal adhesion kinase via two separate pathways in human umbilical vein endothelial cells. J Biol Chem 279(5):3497–3508PubMed
Metadata
Title
Emerging Roles of PAR-1 and PAFR in Melanoma Metastasis
Authors
Vladislava O. Melnikova
Gabriel J. Villares
Menashe Bar-Eli
Publication date
01-12-2008
Publisher
Springer Netherlands
Published in
Cancer Microenvironment / Issue 1/2008
Print ISSN: 1875-2292
Electronic ISSN: 1875-2284
DOI
https://doi.org/10.1007/s12307-008-0002-7

Other articles of this Issue 1/2008

Cancer Microenvironment 1/2008 Go to the issue

Review Paper

Regulation of Tumor Progression by Extracellular Galectin-3

Review Paper

The Prometastatic Microenvironment of the Liver

Review Paper

Abnormal Growth Factor/Cytokine Network in Gastric Cancer

Review Paper

Role of Cancer Microenvironment in Metastasis: Focus on Colon Cancer

Original Paper

Neuroblastoma Cell Death is Induced by Inorganic Arsenic Trioxide (As2O3) and Inhibited by a Normal Human Bone Marrow Cell-Derived Factor

Original Paper

Microenvironment Changes (in pH) Affect VEGF Alternative Splicing
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits